Optimising heart failure pharmacotherapy: the ideal combination

Por Cleland, John G F, Dutka, David P
Publicado em 1994

Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1

Por Clarke, Sophie J, McCormick, Liam M, Dutka, David P
Publicado em 2014

Hyperinsulinemia improves ischemic LV function in insulin resistant subjects

Por Heck, Patrick M, Hoole, Stephen P, Khan, Sadia N, Dutka, David P
Publicado em 2010

Assessment of Myocardial Scar; Comparison Between (18)F-FDG PET, CMR and (99)Tc-Sestamibi

Por Crean, Andrew, Khan, Sadia N., Davies, L. Ceri, Coulden, Richard, Dutka, David P.
Publicado em 2009

Impact of VV optimization in relation to left ventricular lead position: an acute haemodynamic study

Por Khan, Fakhar Z., Virdee, Munmohan S., Read, Philip A., Pugh, Peter J., Begley, David, Fynn, Simon P., Dutka, David P.
Publicado em 2011

Coronary collaterals provide a constant scaffold effect on the left ventricle and limit ischemic left ventricular dysfunction in humans

Por Hoole, Stephen P., White, Paul A., Read, Philip A., Heck, Patrick M., West, Nick E., O'Sullivan, Michael, Dutka, David P.
Publicado em 2012

Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus

Por McCormick, Liam M, Heck, Patrick M, Ring, Liam S, Kydd, Anna C, Clarke, Sophie J, Hoole, Stephen P, Dutka, David P
Publicado no Cardiovasc Diabetol (2015)

Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies

Por Giblett, Joel P., Axell, Richard G., White, Paul A., Clarke, Sophie J., McCormick, Liam, Read, Philip A., Reinhold, Johannes, Brown, Adam J., O’Sullivan, Michael, West, Nick E. J., Dutka, David P., Hoole, Stephen P.
Publicado no Cardiovasc Diabetol (2016)